Alport Syndrome Market è segmentato da Drug Class (ACE Inhibitors, ARBs, SGLT2 Inhibitors, Emerging Therapies), da Disease Type (X-linked Alport Syndrome (XLAS), Autosoma ....
I principali attori operanti nel mercato della sindrome di Alport includono Eloxx Pharmaceuticals, Chinook Therapeutics, Travere Therapeutics, Reata Pharmaceuticals, Bayer, River 3 Renal Corp, Calliditas Therapeutics, Novartis, Evotec, Genzyme Corp, TMC Pharma Services Ltd e Shanghai Children's Hospital.
Mercato della Sindrome di Alport